Compare Davita Inc (DVA) vs FedEx Corporation (FDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs FedEx Corporation — how do they compare? Davita Inc trades at $230.51 (market cap $14.92B), while FedEx Corporation trades at $313 (market cap $74.84B). The key difference: FedEx Corporation is far larger — about 5× Davita Inc's market cap, and FedEx Corporation pays a 1.56% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | FDX | |
|---|---|---|
Market Cap | $14.92B | $74.84B |
Sector | Health | Industrials |
52-Week High | $235.71 | $338.75 |
52-Week Low | $103.87 | $174.81 |
Enterprise Value | $27.47B | $104.47B |
Dividend Yield | — | 1.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
FedEx (FDX) trades at $313.74, down 0.3% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $6.31, beating expectations, and is executing strategic moves like the $1.4 billion sale of its supply chain unit to CMA CGM. Valuation ratios appear reasonable with a P/E of 16.91 and P/S of 0.79, while analyst consensus remains positive with a $358.80 price target.
The outlook is mixed; cost-cutting initiatives and debt reduction via a $4.15 billion tender offer support fundamentals, but weak shipping demand and margin pressures pose risks. Upside depends on margin recovery from DRIVE and Network 2.0 programs, though competitive threats from Amazon logistics and economic sensitivity warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →
